Treatment  with apixaban in a patient with recent chronic subdural haematoma: a case report

Laura Massobrio; Gian Marco Rosa; Fabrizio Montecucco; Alberto Valbusa

doi:10.4414/smw.2015.14048

Peer reviewed clinical letter

Vol. 145 No. 0304 (2015)

Treatment with apixaban in a patient with recent chronic subdural haematoma: a case report

Laura Massobrio
Gian Marco Rosa
Fabrizio Montecucco
Alberto Valbusa

DOI: https://doi.org/10.4414/smw.2015.14048
Cite this as:: Swiss Med Wkly. 2015;145:w14048
Published: 11.01.2015

References

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.
Connolly SJ1, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al.; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17.
Ducruet AF, Grobelny BT, Zacharia BE, Hickman ZL, DeRosa PL, Anderson K, et al. The surgical management of chronic subdural hematoma. Neurosurg Rev. 2012;35(2):155–69.
European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al.; ESC Committee for Practice Guidelines. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12(10):1360–420.
Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, et al.; ARISTOTLE Committees and Investigators. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63(11):1082–7.
Marquie C, De Geeter G, Klug D, Kouakam C, Brigadeau F, Jabourek O, et al. Post-operative use of heparin increases morbidity of pacemaker implantation. Europace. 2006;8(4):283–7.
Airaksinen KE, Korkeila P, Lund J, Ylitalo A, Karjalainen P, Virtanen V, et al. Safety of pacemaker and implantable cardioverter-defibrillator implantation during uninterrupted warfarin treatment – the FinPAC study. Int J Cardiol. 2013;168(4):3679–82.
Bhave PD, Knight BP. Optimal strategies including use of newer anticoagulants for prevention of stroke and bleeding complications before, during, and after catheter ablation of atrial fibrillation and atrial flutter. Curr Treat Options Cardiovasc Med. 2013;15(4):450–66.

How to Cite

1.

Massobrio L, Rosa GM, Montecucco F, Valbusa A. Treatment with apixaban in a patient with recent chronic subdural haematoma: a case report. Swiss Med Wkly [Internet]. 2015 Jan. 11 [cited 2024 Nov. 26];145(0304):w14048. Available from: https://smw.ch/index.php/smw/article/view/1967

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Most read articles by the same author(s)

Vincent Braunersreuther, François Mach, Fabrizio Montecucco, Statins and stent thrombosis , Swiss Medical Weekly: Vol. 142 No. 0708 (2012)
Federico Carbone, Fabrizio Montecucco, François Mach, Update on evidence for treatment with ranolazine in stable angina , Swiss Medical Weekly: Vol. 143 No. 4344 (2013)
Alberto Valbusa, Matteo Paganini, Gianluca Secchi, Fabrizio Montecucco, Gian Marco Rosa, What happened to a thrombus during apical ballooning syndrome: a case report , Swiss Medical Weekly: Vol. 143 No. 1920 (2013)
Alberto Valbusa, Fabrizio Montecucco, Gian Marco Rosa, Reply to “Management of left ventricular thrombosis in patients with apical aneurysm” , Swiss Medical Weekly: Vol. 143 No. 4950 (2013)

[1] Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.

[2] Connolly SJ1, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al.; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17.

[3] Ducruet AF, Grobelny BT, Zacharia BE, Hickman ZL, DeRosa PL, Anderson K, et al. The surgical management of chronic subdural hematoma. Neurosurg Rev. 2012;35(2):155–69.

[4] European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al.; ESC Committee for Practice Guidelines. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12(10):1360–420.

[5] Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, et al.; ARISTOTLE Committees and Investigators. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63(11):1082–7.

[6] Marquie C, De Geeter G, Klug D, Kouakam C, Brigadeau F, Jabourek O, et al. Post-operative use of heparin increases morbidity of pacemaker implantation. Europace. 2006;8(4):283–7.

[7] Airaksinen KE, Korkeila P, Lund J, Ylitalo A, Karjalainen P, Virtanen V, et al. Safety of pacemaker and implantable cardioverter-defibrillator implantation during uninterrupted warfarin treatment – the FinPAC study. Int J Cardiol. 2013;168(4):3679–82.

[8] Bhave PD, Knight BP. Optimal strategies including use of newer anticoagulants for prevention of stroke and bleeding complications before, during, and after catheter ablation of atrial fibrillation and atrial flutter. Curr Treat Options Cardiovasc Med. 2013;15(4):450–66.